Literature DB >> 21557949

Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.

Philip J Aston1, Gianne Derks, Adewale Raji, Balaji M Agoram, Piet H van der Graaf.   

Abstract

We consider the relationship between the target affinity of a monoclonal antibody and its in vivo potency. The dynamics of the system is described mathematically by a target-mediated drug disposition model. As a measure of potency, we consider the minimum level of the free receptor following a single bolus injection of the ligand into the plasma compartment. From the differential equations, we derive two expressions for this minimum level in terms of the parameters of the problem, one of which is valid over the full range of values of the equilibrium dissociation constant K(D) and the other which is valid only for a large drug dose or for a small value of K(D). Both of these formulae show that the potency achieved by increasing the association constant k(on) can be very different from the potency achieved by decreasing the dissociation constant k(off). In particular, there is a saturation effect when decreasing k(off) where the increase in potency that can be achieved is limited, whereas there is no such effect when increasing k(on). Thus, for certain monoclonal antibodies, an increase in potency may be better achieved by increasing k(on) than by decreasing k(off).
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21557949     DOI: 10.1016/j.jtbi.2011.04.030

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  22 in total

1.  Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development.

Authors:  Piet H van der Graaf; Neil Benson
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

2.  Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.

Authors:  Abhinav Tiwari; Anson K Abraham; John M Harrold; Anup Zutshi; Pratap Singh
Journal:  AAPS J       Date:  2016-12-21       Impact factor: 4.009

3.  Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  MAbs       Date:  2016-11-28       Impact factor: 5.857

4.  Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.

Authors:  Joseph Ryan Polli; Frank A Engler; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2018-10-12       Impact factor: 3.534

5.  Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology.

Authors:  Neil Benson; Piet H van der Graaf; Lambertus A Peletier
Journal:  J Math Biol       Date:  2012-12-02       Impact factor: 2.259

Review 6.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

7.  A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.

Authors:  Philip J Aston; Gianne Derks; Balaji M Agoram; Piet H van der Graaf
Journal:  J Math Biol       Date:  2013-04-17       Impact factor: 2.259

8.  Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

Authors:  Anjaneya P Chimalakonda; Rajbharan Yadav; Punit Marathe
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

Review 9.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

10.  Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.

Authors:  Yulia Vugmeyster; Cynthia Rohde; Mylene Perreault; Ruth E Gimeno; Pratap Singh
Journal:  MAbs       Date:  2013-03-25       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.